MedTrace Logo

Effect of Low Dose ColchiciNe on the InciDence of POAF

NCT03015831 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 254

Last updated 2020-05-01

No results posted yet for this study

Summary

The prior End-AF study by the same group showed that 1 mg of colchicine didn't decrease the incidence of AF after cardiac surgery. The current study, End-AF Low Dose Study, will test 0.5 mg colchicine vs. placebo in preventing AF after cardiac surgery.

Conditions

Interventions

DRUG

Colchicine

Colchicine will be given to open heart surgery patients

DRUG

Placebo Oral Tablet

Placebo Oral Tablet will be given to open heart surgery patients according to randomization

Sponsors & Collaborators

  • Jordan Collaborating Cardiology Group

    lead OTHER

Principal Investigators

  • Ramzi Tabbalat, MD, FACC · JCC Group, Cardiology Department, Khalidi Medical Center, Amman, Jordan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-02
Primary Completion
2019-04-01
Completion
2019-05-01

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03015831 on ClinicalTrials.gov